cd33*cd3 bsab
mAbexperimentalBi-specific
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2021 (NCT05077423)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05077423 | Phase 1 | Dec 31, 2021 | Harvard University, National Cancer Institute (NCI), Y-Mabs, Inc |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2021 |
| Y-Mabs, Inc | For profit | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1